Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABBV-787
- Development stage
- Discontinued
- Lead developer
- AbbVie
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
ABBV-787 is an investigational monoclonal antibody-drug conjugate (ADC) developed by AbbVie for the treatment of relapsed and refractory acute myeloid leukemia (AML). The drug targets CD33, a cell surface antigen commonly expressed on AML cells, and is conjugated to a bromodomain and extra-terminal domain (BET) degrader as its cytotoxic payload. By binding to CD33 on leukemic cells, ABBV-787 delivers the BET inhibitor directly into malignant cells, aiming to induce cell death through inhibition of BET proteins involved in cancer cell proliferation and survival. The drug was administered intravenously in clinical trials[1][3][5][6].
02
Targets
BET (BET family proteins)CD33 (Myeloid cell surface antigen CD33)
Beyond the preview
Go deeper on ABBV-787.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABBV-787.